Assess whether a CMC change is a comparability or a new product (d9fecf)

Situation

Clinical and Evidence Strategy work in an RWE group proposing a post-marketing study instead of a new RCT now turns on a CMC change is because a literature paper the 505(b)(2) package leans on getting retracted put RWE protocol that may not meet regulator expectations in play. Labeling negotiator should say what RWE protocol that may not meet regulator expectations proves.

Decision

Labeling negotiator in an RWE group proposing a post-marketing study instead of a new RCT must choose A CMC change is a comparability / A new product using RWE protocol that may not meet regulator expectations after a literature paper the 505(b)(2) package leans on getting retracted.

Hypotheses to test

• Labeling negotiator can defend A CMC change is a comparability from RWE protocol that may not meet regulator expectations after a literature paper the 505(b)(2) package leans on getting retracted in a Pharma & Life Sciences challenge.
• Labeling negotiator cannot defend A CMC change is a comparability from RWE protocol that may not meet regulator expectations; A new product is what the extract actually supports after a literature paper the 505(b)(2) package leans on getting retracted.
• A literature paper the 505(b)(2) package leans on getting retracted never reached the population in RWE protocol that may not meet regulator expectations — reopen intake, do not close a CMC change is.
• Two facts in RWE protocol that may not meet regulator expectations after a literature paper the 505(b)(2) package leans on getting retracted conflict for labeling negotiator; hold this Clinical and Evidence Strategy file.

Analysis required

• Trace CMC, labeling, or pharmacovigilance facts in RWE protocol that may not meet regulator expectations after a literature paper the 505(b)(2) package leans on getting retracted.
• Separate an isolated adverse event from a systemic quality issue.
• Test a protocol deviation versus a safety signal versus a filing gap on a CMC change is.
• For this Pharma & Life Sciences Clinical and Evidence Strategy file, read RWE protocol that may not meet regulator expectations against a literature paper the 505(b)(2) package leans on getting retracted and write the one fact that would move a CMC change is for labeling negotiator.

Recommendation